8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Probable progressive supranuclear palsy in a patient with chronic schizophrenia: A case report

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rare neurodegenerative disorders may be considered in the differential diagnosis of Parkinsonism in patients with schizophrenia who show worsening signs of Parkinsonism under treatment with antipsychotics. To the best of our knowledge, the present study is the first report describing probable progressive supranuclear palsy (PSP) in a patient with chronic schizophrenia. A 64-year-old man presented with hallucinations, delusions and asociality. He had received treatment with both typical and atypical antipsychotics for ~13 years. He began experiencing short-term memory impairment and bradykinesia two years before presentation, and then showed increased dysphagia, upper-limb muscle rigidity, extrapyramidal symptoms, vision loss and photophobia. Psychological manifestations included chronic depression, irritability and, occasionally, euphoria. His gait worsened, leading to repeated falls. Antipsychotics were discontinued, and the patient was almost completely dependent on a wheelchair in daily life. In a neurology consultation, he was diagnosed with probable progressive supranuclear palsy-Richardson's syndrome presenting as vertical supranuclear gaze palsy and prominent postural instability with falls. Brain magnetic resonance imaging (MRI) revealed atrophy of the mesencephalic tegmentum, and 123I-ioflupane single-photon emission computed tomography (SPECT) revealed reduced bilateral striatal reuptake. Overall, PSP should be considered in patients with schizophrenia with worsening Parkinsonism, especially when it is accompanied by supranuclear ophthalmoplegia, pseudobulbar palsy, dysarthria and dystonic stiffness of the neck and upper body. In the present case, the combination of brain MRI and 123I-ioflupane SPECT helped to discriminate PSP from other Parkinsonian syndromes, including drug-induced Parkinsonism, in the differential diagnosis.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

          PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, have excellent specificity, but their sensitivity is limited for variant PSP syndromes with presentations other than Richardson's syndrome.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Parkinson's Disease and Parkinsonism

            Parkinson's disease is a progressive neurodegenerative disease characterized by tremor and bradykinesia and is a common neurologic ailment. Male sex and advancing age are independent risk factors and, as the population ages, is taking an increasing toll on productivity and medical resources. There are a number of other extrapyramidal conditions that can make the diagnosis challenging. Unlike other neurodegenerative diseases, idiopathic Parkinson's disease has effective treatments that mitigate symptoms. Medications can improve day-to-day function and, in cases where medication does not give a sustained benefit or has significant side effects, treatments like deep brain stimulation result in improved quality of life.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.

              This article-the first of a five-part series-discusses possible causes, symptoms, diagnosis, and goals for treatment of Parkinson's disease. Identifying diseases that have similar presentations is an important component of the diagnostic process.
                Bookmark

                Author and article information

                Journal
                Exp Ther Med
                Exp Ther Med
                ETM
                Experimental and Therapeutic Medicine
                D.A. Spandidos
                1792-0981
                1792-1015
                July 2022
                01 June 2022
                01 June 2022
                : 24
                : 1
                : 484
                Affiliations
                [1 ]Department of Neuropsychiatry, Kinan Psychiatric Center, Tanabe, Wakayama 646-0015, Japan
                [2 ]Department of Neuropsychiatry, Wakayama Medical University, Wakayama, Wakayama 641-8510, Japan
                [3 ]Department of Neurology, Kinan Hospital, Tanabe, Wakayama 646-8588, Japan
                Author notes
                Correspondence to: Dr Akira Kita, Department of Neuropsychiatry, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama 641-8510, Japan akita@ 123456wakayama-med.ac.jp

                Abbreviations: DIP, drug-induced Parkinsonism; EPS, extrapyramidal symptoms; MDS, International Parkinson's and Movement Disorder Society; MRI, magnetic resonance imaging; MSA, multiple system atrophy; PD, Parkinson's disease; PSP, progressive supranuclear palsy; PSP-RS, progressive supranuclear palsy-Richardson's syndrome; SPECT, single-photon emission computed tomography

                Article
                ETM-24-1-11411
                10.3892/etm.2022.11411
                9214598
                63b8577e-5aa4-4529-9ef5-c1b16f8fb8fd
                Copyright: © Kita et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                : 28 February 2022
                : 16 May 2022
                Funding
                Funding: No funding was received.
                Categories
                Case Report

                Medicine
                progressive supranuclear palsy-richardson's syndrome,schizophrenia,parkinsonism,magnetic resonance imaging,case report

                Comments

                Comment on this article